Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of CB-839 Capsule vs Tablet
NCT02944435Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telaglenastat in solid tumor (2 arms), sponsored by Calithera Biosciences. Primary endpoints: Area Under the Curve, Maximum Concentration and 4 more. Started Oct 2016; status: completed.
02
Drugs
telaglenastat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02944435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944435.